Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31810797

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jan
First author
Rini BI

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):9-11. doi: 10.1016/S1470-2045(19)30781-8.
    note
    Source null
    related pmid
    31810798
    relationship
    Comment in
  2. citation
    Ann Transl Med. 2020 Aug;8(16):1037. doi: 10.21037/atm.2020.03.217.
    note
    Source null
    related pmid
    32953837
    relationship
    Comment in

Authors and identifiers

  1. name
    Rini BI
    type
    Author
  2. name
    Pal SK
    type
    Author
  3. name
    Escudier BJ
    type
    Author
  4. name
    Atkins MB
    type
    Author
  5. name
    Hutson TE
    type
    Author
  6. name
    Porta C
    type
    Author
  7. name
    Verzoni E
    type
    Author
  8. name
    Needle MN
    type
    Author
  9. name
    McDermott DF
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rini BI
    type
    Author
  2. name
    Pal SK
    type
    Author
  3. name
    Escudier BJ
    type
    Author
  4. name
    Atkins MB
    type
    Author
  5. name
    Hutson TE
    type
    Author
  6. name
    Porta C
    type
    Author
  7. name
    Verzoni E
    type
    Author
  8. name
    Needle MN
    type
    Author
  9. name
    McDermott DF
    type
    Author
bibliography ids
  1. nci-bib-eae68f0e61a55437a91434a7
book metadata
content sha256
89b0874aedc50619eb97abc8a92f2a6b3a79f62ec6416877db77c761ea78d2e1
document type
citation
dois
  1. 10.1016/S1470-2045(19)30735-1
electronic publication date
display
2019 Dec 3
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31810797
immutable id
pubmed:31810797@89b0874aedc50619eb97abc8a92f2a6b3a79f62ec6416877db77c761ea78d2e1
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
95-104
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):9-11. doi: 10.1016/S1470-2045(19)30781-8.
    note
    Source null
    related pmid
    31810798
    relationship
    Comment in
  2. citation
    Ann Transl Med. 2020 Aug;8(16):1037. doi: 10.21037/atm.2020.03.217.
    note
    Source null
    related pmid
    32953837
    relationship
    Comment in
outcomes validated
false
pmid
31810797
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
e2ee6cc6476c9d5ef8ba189fec1a6c8fcc182adf2552dc7690471b090e4e64ed
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Jan
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31810797/
title
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Preserved source evidence · Not medical advice